Saxenda (liraglutide 3 mg) / Novo Nordisk - LARVOL DELTA

Drugs and devices for weight management. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Comparison table: Some drugs for weight management. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal

Cost-Consequence Analysis of Semaglutide vs. Liraglutide for Managing Obese Prediabetic and Diabetic Patients in Saudi Arabia: A Single-Center Study. (PubMed, Healthcare (Basel)) - " Semaglutide 1.0 mg weekly seems to be more effective and cost-saving in managing prediabetes, diabetes, and obesity compared to Liraglutide 3.0 mg daily. Future studies should examine these findings using a more representative sample and a robust study design."

Journal • Cardiovascular • Genetic Disorders • Metabolic Disorders • Obesity • Oncology • Type 2 Diabetes Mellitus

Hypersensitivity to liraglutide: A case report. (PubMed, Asia Pac Allergy) - "Saxenda (liraglutide) is approved for the treatment of type 2 diabetes mellitus and chronic weight management in adults with obesity. Literature suggests variability in allergic reactions among glucagon-like peptide-1 receptor agonists, highlighting the need for further research. Our case underscores the importance of individualized management in treating adverse reactions to liraglutide in obese patients without type 2 diabetes mellitus."

Journal • Allergy • Dermatology • Diabetes • Genetic Disorders • Immunology • Metabolic Disorders • Obesity • Pruritus • Type 2 Diabetes Mellitus

Liraglutide for obesity in HIV (LIROH): a clinical trial evaluating acceptability, impact on cardiometabolic risks & gut immunity of GLP-1 receptor agonists in South Africa (IAS-HIV 2025) - "Participants received liraglutide 3.0mg daily plus lifestyle counseling for 12 weeks ("on-treatment") and were followed for 12 more weeks once off-treatment ("wash-out"). Liraglutide was highly acceptable and reduced important cardiometabolic risk markers and depressive symptoms; it also significantly improved local gut immune reconstitution, which may further decrease inflammation-related complications in PLWH. These data demonstrate high potential for unique GLP-1RA benefits in PLWH and support the need for larger trials in PLWH in the African region."

Clinical • Late-breaking abstract • CNS Disorders • Diabetes • Genetic Disorders • Human Immunodeficiency Virus • Infectious Disease • Inflammation • Metabolic Disorders • Obesity • CD4

Impact of Liraglutide 3.0 mg on Metabolic Dysfunction-Associated Steatotic Liver Disease in Individuals with Obesity: A Real-World Study. (PubMed, Ann Nutr Metab) - "Liraglutide 3.0 mg improved surrogate markers of MASLD in individuals with obesity, suggesting it may be a promising approach to address both conditions concurrently."

Journal • Real-world evidence • Fibrosis • Gastroenterology • Genetic Disorders • Hepatocellular Cancer • Hepatology • Immunology • Liver Cirrhosis • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • Obesity • Oncology • Solid Tumor

Effects of Liraglutide on Body Composition Distribution in Adolescents with Refractory Obesity Post-Vertical Sleeve Gastrectomy (ENDO 2025) - "Liraglutide 3.0 mg/d for 16 weeks reduced total and subcomponent fat and lean mass in adolescents with obesity post-VSG. 35% of all weight lost was lean mass. Change in trunk fat mass was positively correlated with liraglutide-associated change in fasting glucose."

Gastrointestinal Disorder • Genetic Disorders • Obesity

Saxenda: “Extension of indication to include the use of SAXENDA for weight management in children from the age of 6 years to less than 12 years based on results from study NN8022- 4392…as a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 34.0 of the RMP has also been submitted.” (European Medicines Agency) - CHMP Final Minutes of the meeting on 24 - 27 Feb 2025: “The committee adopted a 2nd request for supplementary information with a specific timetable”

CHMP • Obesity

Advancements and challenges in the management of obesity using pharmacotherapy (Review). (PubMed, Exp Ther Med) - "However, additional research is necessary to address the side effects associated with AOMs, particularly those affecting the GI tract, gallbladder and pancreas. Furthermore, the potential of NK2R activation merits investigation in clinical trials, particularly in high-risk patients."

Journal • Review • Diabetes • Gastrointestinal Disorder • Genetic Disorders • Metabolic Disorders • Obesity

Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 23-26 October 2023 (European Medicines Agency) - "EMA’s safety committee (PRAC) has concluded that the available evidence does not support a causal association between the Glucagon-Like Peptide-1 Receptor Agonists (GLP-1) - exenatide, liraglutide, dulaglutide, semaglutide, and lixisenatide - and cancer of the thyroid (a small gland in the front and lower part of the neck which makes and releases hormones)....The MAHs for liraglutide- (including Victoza, Saxenda, Xultophy), semaglutide- (including Ozempic, Rybelsus, Wegovy), exenatide- (including Bydureon, Byetta), dulaglutide- (i.e.Trulicity) and lixisenatide- (including Lyxumia, Suliqua) containing products should continue to monitor these events closely, including any new publications, as part of their pharmacovigilance activities and report any new evidence on this issue in their Periodic Safety Update Reports (PSURs)."

European regulatory • Diabetes • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Weight loss maintenance with exercise but not with GLP-1 receptor agonist treatment decreases atherosclerosis development (EASD 2025) - P4 | "Of 215 total participants, 195 participants completed an 8-week low-calorie diet (see Table 1 for baseline characteristics) and were randomly assigned to 52 weeks of weight loss maintenance with or without exercise and glucagon-like peptide-1 receptor agonist liraglutide 3.0 mg/day or placebo treatment. Exercise, but not incretin-based therapy, decreased atherosclerosis development during weight loss maintenance. Since both exercise and incretin-based treatment maintained weight loss, this suggests that exercise plays a key role in mitigating cardiovascular risk factors in a weight-independent manner."

Clinical • Diabetes • Metabolic Disorders • Obesity • ICAM1 • IFNG • IL6 • VCAM1

Outcomes of Different Lifestyle Approaches in a Multicentre, Open-Label, Parallel-Group, Randomised Controlled Trial of the Effectiveness of Integrating a Pragmatic Pathway for Prescribing Liraglutide 3.0 mg in Weight Management Services (STRIVE Study). (PubMed, Metabolites) - "By week 104, Dublin participants maintained a mean weight loss of -4.4% (SD ± 5.7%) while UK participants had a mean weight gain of 0.37% (SD ± 7.6%) (p < 0.05). The integration of meal replacements as part of usual care may have contributed to the greater and sustained weight loss observed in the Dublin cohort compared to other SWMS in the UK."

Journal • Cardiovascular • CNS Disorders • Depression • Genetic Disorders • Hypertension • Mood Disorders • Obesity • Psychiatry

Effect of Meal Replacement Compared with Liraglutide 3.0 mg on Weight Loss and Hepatic Steatosis before Bariatric Surgery—A Randomised Study (ADA 2025) - "Liraglutide achieved numerically greater, albeit non-significant improvement of weight and non-invasive markers of MAFLD after an 18-week intervention prior to bariatric surgery compared to a dietary intervention with a meal replacement product."

Bariatric surgery • Clinical • Surgery • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease

The effect of weight loss and glucagon-like peptide-1 receptor agonist on structural changes in knee osteoarthritis: secondary analysis of the randomised, placebo-controlled LOSEIT trial (EULAR 2025) - "If successfully achieving at least a 5% weight loss (during an 8-week intensive dietary intervention (IDI) period) participants were randomised to receive either subcutaneously administered liraglutide 3 mg/day or identically appearing placebo throughout the 52-week main trial period (weeks 0 through 52; i.e., 60 weeks in total)... While the results partially indicate a potentially favourable effect in the GLP-1RA group, the observed difference in structural knee OA changes on radiographs compared to placebo did not reach statistical significance. Further research should investigate whether treatment with more potent GLP-1 receptor agonists could lead to a more substantial improvement in structural knee OA."

Clinical • Genetic Disorders • Immunology • Musculoskeletal Pain • Obesity • Orthopedics • Osteoarthritis • Pain • Rheumatology

Pregnancy warning to women taking Ozempic and Mounjaro after ‘baby boom’ (The Independent) - "Women using weight-loss injections are being urged to use effective contraception, following the Medicines and Healthcare products Regulatory Agency (MHRA)'s first public alert on the use of contraception alongside weight loss and diabetes jabs. The MHRA issued the warning amid concerns that the medications may not be used safely. There have been previous reports linking the injections to a 'baby boom,' with some women reporting unexpected pregnancies, dubbed 'Ozempic babies,' despite using contraception. To date, the MHRA has received over 40 reports of pregnancies among women using these drugs. The drugs in question include Ozempic, Mounjaro, Wegovy, Saxenda, and Victoza, all of which are glucagon-like peptide-1 receptor agonists (GLP-1 or GLP-1 RAs)."

Commercial • Obesity • Type 2 Diabetes Mellitus

Maximizing Outcomes: Synchronizing Liraglutide And Tailored Exercise In Weight Loss - A Case Study (ACSM 2025) - "X began on an incremental protocol of liraglutide (Saxenda), starting at 0.6 mg daily and gradually increasing to the maximum dose of 3 mg daily over several weeks. A comprehensive metabolic panel revealed normal thyroid and glucose levels, ruling out hypothyroidism and Type 2 Diabetes. Exercise testing showed:VT VO2: 17.6 ml/kg/minVT HR: 114 bpmVO2 Max: 36.8 ml/kg/minMax HR: 177 bpmBody composition and anthropometric measures, including weekly neck, arm, waist, and hip circumferences, were recorded to track progress. FINAL WORKING DIAGNOSIS: The final diagnosis was primary obesity complicated by central adiposity and functional limitations.TREATMENT AND OUTCOMES:Mr."

Case study • Clinical • Cardiovascular • Diabetes • Endocrine Disorders • Fatigue • Genetic Disorders • Metabolic Disorders • Musculoskeletal Diseases • Musculoskeletal Pain • Obesity • Orthopedics • Pain • Type 2 Diabetes Mellitus

Symptomatic adverse events and patient-reported outcomes related to incretin-based medicines for obesity: a systematic review involving >400, 000 subjects (ECO 2025) - "Treatment arms for the maintenance dose (or highest dose where maintenance was not used) were selected (e.g. liraglutide 3 mg, semaglutide 2.4 mg, and tirzepatide 15 mg), where a study had more than one treatment arm for the same IBT. This systematic review of the literature confirms that GI AEs are the most commonly reported symptomatic AEs, and that their incidence varies between IBTs and studies. Clinicians should keep the AE profile of IBTs in mind when making therapy decisions and consider mitigation strategies including nutritional solutions. Abbreviations: AE, adverse event; IBT, incretin-based therapy; N, number of patients; n, number of publications; RWE, real-world evidence."

Adverse events • Clinical • Patient reported outcomes • Review • Alopecia • Constipation • Fatigue • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Obesity • Pain

The effects of a two-week hypocaloric meal replacement compared to an established liraglutide therapy on body composition and non-invasive markers of MAFLD before bariatric surgery (ECO 2025) - " We investigated the effects of a hypocaloric, high-fiber, high-protein diet based on three daily meal replacement products (Hepafast®) compared to a treatment with liraglutide 3.0 mg, which had already been initiated 16 weeks earlier as part of the preparation for bariatric surgery. 49 patients (age 40±11yrs, BMI 44.6±5.6 kg/m², 78% women) were included. At baseline, the liraglutide group had a numerically, but not significantly lower weight (p=0.193), BMI (p=0.206) and waist circumference (p=0.236) compared to the meal replacement group. Mean weight loss after 2 weeks was significantly greater in the meal replacement group (p=0.019)."

Bariatric surgery • Non-invasive • Surgery • Genetic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • Obesity

Exercise improves cardiorespiratory fitness and functional performance during weight loss maintenance with GLP-1 receptor agonist treatment (ECO 2025) - P4 | " This is a secondary analysis of the S-LiTE trial (NCT04122716), which involved 195 adults with obesity who completed an 8-week low-calorie diet and were subsequently randomized (1:1:1:1 ratio) into four groups for 52 weeks: moderate-to-vigorous-intensity exercise program plus placebo (exercise alone), GLP-1 RA liraglutide 3 mg once-daily plus usual activity (liraglutide alone), exercise plus liraglutide (combination treatment), or placebo plus usual activity (placebo)... Moderate-to-vigorous-intensity exercise during GLP-1 RA treatment for weight maintenance improved cardiorespiratory fitness and functional performance and increased relative muscle strength despite additional weight loss. In contrast, GLP-1 RA treatment alone did not improve cardiorespiratory fitness nor functional performance. These findings highlight the importance of incorporating structured exercise into medical obesity treatments to optimize physical fitness and function during weight loss..."

Clinical • Genetic Disorders • Obesity

Maximizing outcomes: synchronizing liraglutide and tailored exercise in weight loss - a case study (ECO 2025) - "The patient was placed on a progressive liraglutide (Saxenda) protocol, titrated up to 3 mg daily, complemented by a customized exercise regimen totaling 300 minutes per week. The results suggest that personalized exercise can amplify the effects of liraglutide, fostering weight loss and improved physical capacity. The findings support a combined intervention approach for individuals with long-standing obesity who have struggled with lifestyle modification alone, underscoring the value of individualized, dual-modality treatment for achieving and sustaining weight loss while improving overall fitness and health outcomes."

Case study • Clinical • Cardiovascular • Diabetes • Endocrine Disorders • Fatigue • Genetic Disorders • Metabolic Disorders • Musculoskeletal Diseases • Musculoskeletal Pain • Obesity • Orthopedics • Pain • Type 2 Diabetes Mellitus

Real-world data on the effectiveness of liraglutide (Saxenda) and naltrexone/bupropion (Mysimba) on weight loss outcomes up to 2 years in clinical practice (ECO 2025) - No abstract available

Clinical • Late-breaking abstract • Real-world • Real-world evidence

LITOP: Liraglutide Treatment in Obese Infertile PCOS Women (clinicaltrials.gov) - P4 | N=890 | Recruiting | Sponsor: Peking University Third Hospital | Not yet recruiting ➔ Recruiting | Trial completion date: Jun 2028 ➔ Dec 2029 | Initiation date: Feb 2025 ➔ May 2025 | Trial primary completion date: Jun 2028 ➔ May 2029

Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date • Genetic Disorders • Infertility • Obesity • Polycystic Ovary Syndrome • Sexual Disorders

Saxenda - opinion on variation to marketing authorisation (European Medicines Agency) - "On 22 May 2025, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending a change to the terms of the marketing authorisation for the medicinal product Saxenda. The marketing authorisation holder for this medicinal product is Novo Nordisk A/S...The CHMP adopted an extension to the existing indication to include treatment of children aged 6 to less than 12 years, as follows: Children (6 to <12 years): Saxenda is indicated as an adjunct to healthy nutrition and increased physical activity for weight management in children from the age of 6 to <12 years with: obesity (BMI ≥95th percentile) and body weight ≥45 kg....Treatment with Saxenda should be discontinued and re-evaluated if patients have not lost at least 4% of their BMI or BMI z score after 12 weeks on the 3.0 mg/day or maximum tolerated dose."

CHMP • Obesity

Analysis of Employer Coverage of Weight Loss Therapies (ISPOR 2025) - "71% of workers have access to Wegovy through their employer, and 54% have access to Saxenda. This analysis will help policymakers gain a better understanding of employee coverage decisions so they can develop optimal policies that balance the financial costs against the health and economic benefits of weight loss therapies. Further research is needed on the drivers behind the correlations presented in this analysis. The findings will also help manufacturers conduct out-reach to employers, and appeal to their unique needs, such as the ability to compete for talent and prevention of morbidities that can hinder the ability to work."

Genetic Disorders • Obesity

Are Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Central Nervous System (CNS) Penetrant: A Narrative Review. (PubMed, Neurol Ther) - " Preclinical studies indicate that select GLP-1 RAs are CNS penetrant; whether GLP-1 RAs reproducibly engage neural targets hypothesized to subserve dimensions of psychopathology (e.g., general cognitive functions) remains incompletely characterized."

Journal • Review • Alzheimer's Disease • CNS Disorders • Diabetes • Genetic Disorders • Metabolic Disorders • Movement Disorders • Obesity • Parkinson's Disease